Rankings
▼
Calendar
TGTX Q1 2025 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TGTX
TG Therapeutics, Inc.
$5B
Q1 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$121M
+90.4% YoY
Gross Profit
$105M
87.1% margin
Operating Income
$9M
7.1% margin
Net Income
$5M
4.2% margin
EPS (Diluted)
$0.03
QoQ Revenue Growth
+11.7%
Cash Flow
Operating Cash Flow
-$29M
Free Cash Flow
-$29M
Stock-Based Comp.
$15M
Balance Sheet
Total Assets
$657M
Total Liabilities
$419M
Stockholders' Equity
$237M
Cash & Equivalents
$132M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$121M
$63M
+90.4%
Gross Profit
$105M
$58M
+81.7%
Operating Income
$9M
-$9M
+193.0%
Net Income
$5M
-$11M
+147.3%
Revenue Segments
Product
$120M
99%
Royalty
$605,000
1%
Other Revenue
$558,000
0%
License Revenue
$38,000
0%
← FY 2025
All Quarters
Q2 2025 →